Press Releases

ATLANTA, July 9, 2024 — At this time the American Most cancers Society (ACS) introduced a brand new collaboration with Trial Library, Inc., and the Prostate Most cancers Medical Trials Consortium (PCCTC) to assist a nationwide initiative to speed up the recruitment of Black sufferers to prostate most cancers medical trials.

Regardless of declines in general most cancers mortality in america, deaths from prostate most cancers in Black males characterize the best mortality disparity in oncology. Black males are two to 4 instances extra more likely to die from prostate most cancers than every other racial and ethnic group. Moreover, lower than 5% of members in oncology medical trials are Black males. Medical trials present an avenue for sufferers to contribute to analysis findings for future generations and will provide entry to cutting-edge therapies.

ACS is dedicated to enhancing racial range in medical trials. To extend participation of Black males with prostate most cancers in medical trials, ACS is saying a funding alternative to assist group oncology practices and hospitals of their efforts for medical trial enrollment. Eligible practice-based candidates should have direct affected person interplay and the aptitude to take part in medical trials.

“Diversifying participation in medical trials is essential to reducing prostate most cancers deaths for everybody,” mentioned Dr. William Dahut, chief scientific officer on the American Most cancers Society. “It is time to transfer past phrases and put into motion a plan to assist clinicians and sufferers. ACS is dedicated to supporting analysis and evidence-based care to enhance the well being of all communities.”

To raised assist efforts towards recruitment of sufferers to medical trials, ACS will pair awarded group oncology and urology practices with the Trial Library platform, which gives affected person identification and navigation assist via software program and technology-enabled providers built-in in group practices. To construct upon current infrastructure and promote the sustainability of medical trial enrollment efforts, ACS will assist entry to the PCCTC to assist awarded groups enroll sufferers on hypothesis-driven trials of novel brokers and combos that would extend the lives of sufferers with prostate most cancers. “Championing range, fairness, and inclusivity in participant recruitment and medical analysis practices is a pillar of the PCCTC’s Guiding Rules,” commented Jake Vinson, CEO of PCCTC.

Trial Library has beforehand partnered with the PCCTC to enroll a whole bunch of sufferers with prostate most cancers into medical trials throughout the U.S. “Our progressive collaboration to reinforce analysis capability in community-based settings, the place 85% of sufferers with most cancers obtain care, is important to advancing fairness in whom medical trials serve,” mentioned Dr. Hala Borno, CEO of Trial Library. ACS believes this confirmed and evidence-based strategy will present the required assist that group practices must advance entry to prostate most cancers medical trials for Black sufferers.

ACS will present awardees as much as $200,000 direct prices per yr for 2 years to construct the infrastructure wanted to extend medical trial enrollment. These funds could also be used to assist medical workers concerned in recruitment and trial enrollment in addition to any infrastructure wanted to interact males with prostate most cancers. Profitable purposes shall be these with demonstrated means to take part in medical trials, a historical past of group engagement in areas that embrace a sizeable Black inhabitants, and viable plans to interact these males in medical trials, that may profit from further funds and providers supplied by this initiative via collaboration with the ACS, Trial Library, and the PCCTC. Though this initiative is targeted to bettering entry to trials for Black males, it’s anticipated that this collaboration will improve enrollment of all males into prostate most cancers medical trials.

candidates should submit a letter of intent (LOI) by September 16, 2024 utilizing ProposalCentral that features the title, principal investigator contact info, different key personnel, quantity of sufferers seen, previous and present involvement in medical trials, and a short description of the proposed mission (to not exceed 3 pages). Upon receipt, ACS will present applicable steerage to make sure purposes are inside scope of this funding announcement and extra details about the appliance course of.

This collaboration aligns properly with our current work to unfold the phrase of the Black group in regards to the significance of early detection for prostate most cancers. Earlier this yr, ACS launched  “Change the Odds: Uniting to Enhance Most cancers Outcomes™,” a brand new initiative to begin creating change the place it’s most urgently wanted: in communities disproportionately impacted by breast and prostate most cancers. Via funding from Pfizer, Change the Odds is designed to boost consciousness of no- and low-cost screening, improve entry to assist and navigation providers and supply basic details about medical trial alternatives, together with culturally and linguistically various assets.

For extra details about this funding alternative contact Dr. Joanne Elena at joanne.elena@most cancers.org. 

# # #

Concerning the American Most cancers Society

The American Most cancers Society is a number one cancer-fighting group with a imaginative and prescient to finish most cancers as we all know it, for everybody. For greater than 110 years, we’ve got been bettering the lives of individuals with most cancers and their households as the one group combating most cancers via advocacy, analysis, and affected person assist. We’re dedicated to making sure everybody has a possibility to forestall, detect, deal with, and survive most cancers. To be taught extra, go to most cancers.org or name our 24/7 helpline at 1-800-227-2345. Join with us on Fb, X, and Instagram.